IRX Therapeutics Inc. has appointed biotech industry veterans Mark Leuchtenberger and Monil Shah to president, CEO and director, and as chief operating officer, respectively. IRX’s founder and prior CEO, John W. Hadden, will continue at the company as a director. Leuchtenberger was president, CEO and member of the board at Chiasma Inc., Acusphere Inc. and Rib-X Pharmaceuticals Inc. (now Melinta Therapeutics Inc.). He has also been president and CEO of Targanta Therapeutics Corp. and Therion Biologics Corp. Before this, he was senior officer at Biogen Inc. and co-founded Albor Biologics Inc. and Alvos Therapeutics Inc. Shah brings more than 17 years of pharma and biotech experience in oncology to IRX; most recently, he was medical affairs lead for immuno-oncology at Bristol-Myers Squibb Co. He started his career at Novartis AG in the oncology early development group, and later co-founded Ventrus Biosciences as head of clinical operations and development.
Appointments: IRX Therapeutics, Therachon, Mission Therapeutics and bluebird bio
This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.
More from Executives On The Move
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.
More from Leadership
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.